rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ADAG
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Adagene at Guggenheim healthcare conference: CTLA-4 hopes build
      Nov 9Investing.comADAG
      Adagene doses first patient in Phase 1 cancer drug trial
      Oct 28Investing.comADAG
      Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
      Oct 28Yahoo FinanceADAGINCY
      Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
      Oct 27Yahoo FinanceADAG
      Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer
      Oct 25Yahoo FinanceADAG
      Adagene at Chardan’s 10th Annual Healthcare Conference: bold ctla-4 push
      Oct 20Investing.comADAG
      H.C. Wainwright reiterates Adagene stock rating on TCE progress
      Oct 19Investing.comADAG
      Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
      Oct 16Yahoo FinanceADAG
      Adagene at H.C. Wainwright immune cell engager conference: pipeline gains
      Oct 16Investing.comADAG
      Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
      Oct 14Yahoo FinanceADAG
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Adagene (ADAG) and Inventiva (IVA)

      Tipranks Press Release.

      Sep 30The Globe and MailADAGIVA
      Adagene Announces Finance Executive Resignation Effective September 30, 2026

      Detailed price information for Adagene Inc ADR (ADAG-Q) from The Globe and Mail including charting and trades.

      Sep 26The Globe and MailADAG
      China approves Adagene’s IND application for ADG138 cancer drug
      Sep 22Investing.comADAG
      Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

      Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective therapy with low systemic toxicity Preclinical data demonstrated robust tumor regression in tumor models refractory and/or resistant to Enhertu, along with strong synergy in combination with anti-CTLA-

      Sep 22Yahoo FinanceADAG
      Adagene at H.C. Wainwright conference: higher-dose CTLA-4 push
      Sep 16Investing.comADAG
      Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Adagene (ADAG) and Medtronic (MDT)

      Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

      Sep 15The Globe and MailADAG
      H.C. Wainwright reiterates Adagene stock rating on milestone payments
      Sep 14Investing.comADAG
      Adagene, Third Arc Bio expand partnership with first lead selection
      Sep 10Investing.comADAG
      Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

      Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that Third Arc Bio, Inc. (“Third Arc Bio”) selected the first lead candidate under the amended strategic licensing agreement. The agreement was est

      Sep 10Yahoo FinanceADAG
      Chardan Initiates Adagene at Buy With $9 Price Target
      Sep 10Yahoo FinanceADAG
      Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

      SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”). The milestone achievement is related to a preclinical milestone event for XB404 and resulted in a $2.0 million milestone payment

      Sep 9Yahoo FinanceADAGEXEL
      Adagene Receives Milestone Payment From Exelixis

      Adagene (ADAG) said Wednesday that a preclinical milestone for drug candidate XB404 triggered a $2 m

      Sep 9Yahoo FinanceADAGEXEL
      Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

      Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and...

      Aug 28BarchartADAGINCY

      This is the newest page. Registered accounts read further back.